Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 14 results:
Συντάκτης Τίτλος [ Τύπος(Desc)] Έτος
Φίλτρα: Συντάκτης is Televantou, Despina  [Clear All Filters]
Journal Article
Pentheroudakis, G., Kotoula V., De Roock W., Kouvatseas G., Papakostas P., Makatsoris T., et al. (2013).  Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.. BMC Cancer. 13, 49.
Televantou, D., Karkavelas G., Hytiroglou P., Lampaki S., Iliadis G., Selviaridis P., et al. (2013).  DARPP32, STAT5 and STAT3 mRNA expression ratios in glioblastomas are associated with patient outcome.. Pathol Oncol Res. 19(2), 329-43.
Fountzilas, G., Dafni U., Bobos M., Batistatou A., Kotoula V., Trihia H., et al. (2012).  Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel.. PLoS One. 7(6), e37946.
Batistatou, A., Televantou D., Bobos M., Eleftheraki A. G., Kouvaras E., Chrisafi S., et al. (2013).  Evaluation of current prognostic and predictive markers in breast cancer: a validation study of tissue microarrays.. Anticancer Res. 33(5), 2139-45.
Fountzilas, G., Dafni U., Bobos M., Kotoula V., Batistatou A., Xanthakis I., et al. (2013).  Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy.. BMC Cancer. 13, 163.
Kotoula, V., Krikelis D., Karavasilis V., Koletsa T., Eleftheraki A. G., Televantou D., et al. (2012).  Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS).. BMC Cancer. 12, 342.
Linardou, H., Kotoula V., Kouvatseas G., Mountzios G., Karavasilis V., Samantas E., et al. (2019).  Genotyping and Mutations in Greek Patients With Non-small-cell Lung Cancer: Incidence, Significance and Implications for Treatment.. Cancer Genomics Proteomics. 16(6), 531-541.
Razis, E., Kalogeras K. T., Kotoula V., Eleftheraki A. G., Nikitas N., Kronenwett R., et al. (2012).  Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression.. Clin Breast Cancer. 12(3), 183-93.
Fountzilas, G., Kourea H. P., Bobos M., Televantou D., Kotoula V., Papadimitriou C., et al. (2011).  Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation.. Anticancer Res. 31(9), 3007-18.
Karavasilis, V., Kotoula V., Pentheroudakis G., Televantou D., Lambaki S., Chrisafi S., et al. (2013).  A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas.. J Neurol. 260(6), 1469-80.
Strimpakos, A., Pentheroudakis G., Kotoula V., De Roock W., Kouvatseas G., Papakostas P., et al. (2013).  The prognostic role of ephrin A2 and endothelial growth factor receptor pathway mediators in patients with advanced colorectal cancer treated with cetuximab.. Clin Colorectal Cancer. 12(4), 267-274.e2.
Psyrri, A., Kotoula V., Fountzilas E., Alexopoulou Z., Bobos M., Televantou D., et al. (2014).  Prognostic significance of the Wnt pathway in squamous cell laryngeal cancer.. Oral Oncol. 50(4), 298-305.
Kotoula, V., Lambaki S., Televantou D., Kalogera-Fountzila A., Nikolaou A., Markou K., et al. (2011).  STAT-Related Profiles Are Associated with Patient Response to Targeted Treatments in Locally Advanced SCCHN.. Transl Oncol. 4(1), 47-58.
Iliadis, G., Kotoula V., Chatzisotiriou A., Televantou D., Eleftheraki A. G., Lambaki S., et al. (2012).  Volumetric and MGMT parameters in glioblastoma patients: survival analysis.. BMC Cancer. 12, 3.

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.